1-2 of 2
Peter Mollee
Close
Sort by
Journal Articles

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16

Clinical Trials & Observations
Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon Gibbs, Sophie Lee, Edwin Lee, Kerry Taylor, Tara Cochrane, Craig Wallington-Gates, Fiona Kwok, Nicholas Weber, Ian Kerridge, Helen Weston, P. Joy Ho, Michael Francis Leahy, Noemi Horvath, Andrew Spencer
Journal: Blood Advances
Blood Adv (2024) 8 (14): 3721–3730.
https://doi.org/10.1182/bloodadvances.2023012539
Published: 2024
Includes: Supplemental data
Journal Articles

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance

Joshua W. D. Tobin, Gabrielle Rule, Katherine Colvin, Lourdes Calvente, David Hodgson, Stephen Bell, Chengetai Dunduru, James Gallo, Erica S. Tsang, Xuan Tan, Jonathan Wong, Jessica Pearce, Robert Campbell, Shao Tneh, Sophie Shorten, Melissa Ng, Tara Cochrane, Constantine S. Tam, Emad Abro, Eliza Hawkes, Georgina Hodges, Roopesh Kansara, Dipti Talaulikar, Michael Gilbertson, Anna M. Johnston, Kerry J. Savage, Diego Villa, Kirk Morris, Sumi Ratnasingam, Wojt Janowski, Robert Kridel, Chan Y. Cheah, Michael MacManus, Nicholas Matigian, Peter Mollee, Maher K. Gandhi, Greg Hapgood
Journal: Blood Advances
Blood Adv (2019) 3 (19): 2804–2811.
https://doi.org/10.1182/bloodadvances.2019000458
Published: 2019
Includes: Supplemental data